| Similar Articles |
|---|
 |
BusinessWeek
March 29, 2004
Gene G. Marcial |
Recovery At MedImmune? Flu season is over, but it was a disaster for the No. 6 U.S. biotech, MedImmune (MEDI ). Its ballyhooed FluMist, a nasal-spray flu vaccine, was a flop -- which sent the stock reeling, from 42 in June to 23 now. As a result, some pros are buying: David Katz of Matrix Asset Advisors is confident MedImmune can turn FluMist around, by pricing it lower and educating doctors and consumers about the product.   |
The Motley Fool
April 13, 2007
Brian Lawler |
MedImmune Wants a Mate The biopharma announces the hiring of investment bankers to look for a possible acquirer. Investors, take note. |
The Motley Fool
July 20, 2006
Brian Lawler |
MedImmune Is Easy to Resist Despite the prospects from sales of two new vaccines, it's hard to feel better about this stock. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
The Motley Fool
April 11, 2007
Brian Lawler |
MedImmune Brings Home the Bacon The drugmaker announces preliminary first-quarter financial results. |
The Motley Fool
October 30, 2006
Brian Lawler |
MedImmune's Mediocre Quarter Some patient folks may be willing to wait on MedImmune to turn things around and justify its high valuation, but most other investors should be able to find better value elsewhere in the biotech industry. |
The Motley Fool
March 1, 2004
Alyce Lomax |
MedImmune Under the Weather After short-term setbacks, the biotech turns to the long term. |
The Motley Fool
January 16, 2007
Brian Lawler |
MedImmune's Improved Flu Vaccine One of the three most important traits for a drug's success is convenience in dosing, so investors should be mindful of the FDA's actions on FluMist, MedImmune's nasal spray vaccine, in the coming months. |
The Motley Fool
April 12, 2004
Charly Travers |
Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: MedImmune Will the years ahead continue to be positive for the biopharma? Next year's guidance is for revenue to grow 15% over the $1.3 billion that is expected in 2006. Investors should watch to make sure this is possible. |
The Motley Fool
June 16, 2004
Alyce Lomax |
It's Half-Time at MedImmune The company will slash the price of FluMist. |
The Motley Fool
July 22, 2004
Charly Travers |
Patience With MedImmune While MedImmune has one of the top-selling biologic drugs in the industry, the growth in revenues and earnings is a bit sluggish for what many biotech investors are looking for. |
The Motley Fool
April 21, 2005
Charly Travers |
Synagis Has Some Legs Left The mature drug still generates big numbers for MedImmune. Investors, take note. |
The Motley Fool
May 17, 2007
Brian Lawler |
MedImmune Gets the Thumbs-Up An advisory panel recommends expanded use for one of MedImmune's drugs. |
The Motley Fool
March 2, 2005
Brant David McLaughlin |
Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
The Motley Fool
January 13, 2004
Alyce Lomax |
MedImmune's Sticker Shock Price cut for FluMist is reportedly in the works. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
BusinessWeek
August 8, 2005
Gene G. Marcial |
Symbol Looks Vulnerable Symbol Technologies is giving off bad vibes as shares have slumped from 19 to 11. |
The Motley Fool
February 9, 2007 |
A Shot of Income for MedImmune: Fool by Numbers The pharmaceutical released earning for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 29, 2004
Charly Travers |
MedImmune's Big Gamble FluMist may not be worth the gigantic R&D investment. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
BusinessWeek
April 19, 2004
Gene G. Marcial |
Morgan Stanley Is Going For A Song Morgan Stanley's stock is still at a big discount to its peers -- trading below historic levels based on price-earnings, price-to-book, and price-to-sales ratios. |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
The Motley Fool
October 5, 2004
Alyce Lomax |
No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season. |
The Motley Fool
January 22, 2004
Alyce Lomax |
Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful. |
BusinessWeek
July 31, 2006
Gene G. Marcial |
Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street. |
Fast Company
September 2005
Jennifer Reingold |
CEO See-Ya! David Mott, CEO of Medimmune Inc. is compensated with millions while the company's stock suffers. |
The Motley Fool
May 27, 2005
Rich Duprey |
Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm. |
The Motley Fool
October 6, 2004
Rich Duprey |
Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices. |
